Compare FPI & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | CADL |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 578.8M |
| IPO Year | 2013 | 2021 |
| Metric | FPI | CADL |
|---|---|---|
| Price | $9.74 | $8.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 338.2K | ★ 1.8M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $52,178,000.00 | $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $976.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $4.35 |
| 52 Week High | $13.23 | $9.57 |
| Indicator | FPI | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 32.58 | 48.87 |
| Support Level | $9.44 | $4.80 |
| Resistance Level | $10.59 | $9.42 |
| Average True Range (ATR) | 0.22 | 0.59 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 8.65 | 3.77 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.